Affiliation:
1. Division of Cardiovascular Medicine, Mayo Clinic Hospital , Phoenix, AZ 85054, USA
Abstract
Abstract
Background
Fabry’s disease, an X-linked lysosomal storage disorder, shares cardiac manifestations with hypertrophic cardiomyopathy (HCM). We underscore the importance of considering Fabry’s disease as a differential diagnosis in HCM patients, highlighting genetic testing’s role in cardiomyopathy evaluation.
Case summary
Three male patients with left ventricular hypertrophy were initially diagnosed with HCM but were later found to have Fabry’s disease through genetic testing. Atypical features such as renal dysfunction and conduction abnormalities raised suspicion. Genetic testing confirmed diagnosis, guiding tailored management.
Discussion
Fabry’s disease poses diagnostic challenges due to its resemblance to HCM. Genetic testing enables precise diagnosis and personalized management, especially in cases with atypical presentations. Early recognition and intervention, facilitated by genetic testing, can improve patient outcomes in Fabry’s disease.
Publisher
Oxford University Press (OUP)
Reference9 articles.
1. Cardiac manifestations of Anderson–Fabry disease: results from the international Fabry outcome survey;Linhart;Eur Heart J,2012
2. Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies;Maron;J Am Coll Cardiol,2020
3. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity;Alfares;Genet Med,2015
4. Fabry disease and the heart;Namdar;Swiss Med Weekly,2006
5. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe);Ho;Circulation,2020